Abbvie takes advantage of option and secures potential treatment for Parkinson's
Abbvie acquires the biotech company Mitokinin. In 2021, Abbvie secured prefential right to buy Mitokinin as the former invested money in the latter and its lead candidate: An agent targeting the PINK1 protein, which plays a role in the development of Parkinson’s disease.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.